We are live on ! Find out more
MENS icon

Jyong Biotech

8 hedge funds and large institutions have $4.15M invested in Jyong Biotech in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding

Funds holding: 2 → 8 (+6)

19% more capital inflows, than outflows

Capital inflows: $2.59M | Capital outflows: $2.17M

0.02% more ownership

Funds ownership: 0.12% → 0.14% (+0.02%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
8
Holders Change
+6
Holders Change %
+300%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MENS Hedge Fund Activity: Q3 2025 in Review

8 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q3 2025, worth a combined $4.15M — up 431% from $781K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new MENS positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Citadel Advisors, cutting an estimated $2.1M.

  • 8 institutional investors held Jyong Biotech (MENS) as of Q3 2025, up from 2 in Q2 2025.
  • Funds reported $4.15M of Jyong Biotech stock for Q3 2025, up 431% quarter-over-quarter.
  • 6 funds opened new Jyong Biotech positions in Q3 2025 and 0 closed out, a net change of +6 holders.
  • The largest Jyong Biotech buyer in Q3 2025 was Geode Capital Management, an estimated $1.94M added.
  • The largest Jyong Biotech seller in Q3 2025 was Citadel Advisors, an estimated $2.1M sold.

Based on aggregated 13F filings for Q3 2025.